FDA Clarifies Marketing Limits for Compounded GLP-1 Drugs Amid Ongoing Enforcement Effort

As reported on Becker's Hospital Review, the U.S. Food and Drug Administration (FDA) has issued updated guidance targeting how telehealth companies promote compounded medications, particularly glucagon-like peptide-1 (GLP-1) receptor agonists.…

Continue Reading FDA Clarifies Marketing Limits for Compounded GLP-1 Drugs Amid Ongoing Enforcement Effort

FDA Approves Pembrolizumab–Belzutifan Combination for Adjuvant Treatment of High-Risk Clear Cell RCC

As reported on Pharmaceutical Technology, the US Food and Drug Administration (FDA) has approved a new adjuvant treatment option for adults with clear cell renal cell carcinoma (ccRCC) at elevated…

Continue Reading FDA Approves Pembrolizumab–Belzutifan Combination for Adjuvant Treatment of High-Risk Clear Cell RCC

Glycemic Monitoring Recommended for All Patients Receiving Teprotumumab in Thyroid Eye Disease

Emerging evidence, as reported by the American Academy of Ophthalmology, suggests that glycemic surveillance should be considered for all patients undergoing teprotumumab therapy for thyroid eye disease (TED), regardless of…

Continue Reading Glycemic Monitoring Recommended for All Patients Receiving Teprotumumab in Thyroid Eye Disease

TearSolutions Advances Lacripep® for Neurotrophic Keratitis with FDA Designations and Phase 2 Trial Launch

As reported on Business Wire, TearSolutions, a clinical-stage biotechnology company focused on ophthalmic therapies, has announced key regulatory and clinical progress for its investigational drug Lacripep® in the treatment of…

Continue Reading TearSolutions Advances Lacripep® for Neurotrophic Keratitis with FDA Designations and Phase 2 Trial Launch